Hims & Hers Health announced on Tuesday it will bundle Wegovy with the telehealth platform’s membership through a new collaboration with drugmaker Novo Nordisk. The bundle will offer Novo ...

Shelby Knowles / Bloomberg / Getty Images Hims & Hers Health shares surged Tuesday as the company announced a partnership with Danish drugmaker Novo Nordisk. Hims & Hers users will have access to ...

Hims & Hers (HIMS) stock popped more than 20% in trading early Tuesday after Novo Nordisk (NVO) announced a partnership with it and other telehealth platforms to offer patients access to the ...

In a joint venture with Novo Nordisk, Hims & Hers will dispense all doses of Wegovy to Americans who buy eligible subscriptions, with plans starting at $599 a month. The offering will launch this ...

Hims & Hers Health Inc (NYSE:HIMS) stock is soaring today, up 22.6% at $34.92 at last glance, after news that the telehealth platform will offer Novo Nordisk's (NVO) popular weight-loss drug, Wegovy.

Hims & Hers Health announced a partnership with Novo Nordisk to initially offer the FDA-approved Wegovy drug for weight loss while planning a long-term collaboration on future drugs. The news ...

Patients will be able to access the branded GLP-1 drug, at a discount, through the company's online pharmacy, NovoCare Pharmacy, directly through the telehealth platforms of Hims & Hers ...

Shares of Hims & Hers Health Inc. were headed for their best day ever early Tuesday trading, after the health and wellness company basically teamed up with what was its competition, the maker of ...

Hims & Hers boasts excellent underlying performance, but the stock's current valuation remains uncomfortably high. Despite a 40% drop in stock price, shares are not yet a value, and selling put ...